Pediatric Psychopharmacological and Combined Interventions

  • Margaret Semrud-Clikeman
  • Phyllis Anne Teeter Ellison


Some pediatric disorders with biogenetic or neuropsychological causes may require medical treatments (Wilens, 2001). Most of these disorders, however, require multimodal treatments, where medication is used in combination with other psychosocial and behavioral interventions or therapies. A select list of common medications will be reviewed, including those designed to control ADHD, major depressive disorders, bipolar disorders, psychotic disorders, Tourette syndrome, and seizure disorders. The National Institute of Mental Health (NIMH) has funded a number of studies to investigate the safety and efficacy of medications and psychosocial interventions for common childhood and adolescent disorders. These will be briefly reviewed.


Bipolar Disorder Suicidal Ideation ADHD Symptom Tourette Syndrome Stimulant Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abikoff, M., Hechtman, L., Klein, R., Weiss, K., Fleiss, K., Etcovitch, J., et al. (2004). Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 802–811.CrossRefGoogle Scholar
  2. Balthazor, M. J., Wagner, R. K., & Pelham, W. E. (1991). The specificity of the effects of stimulant medications on classroom-learning related measures of cognitive processing for attention deficit disorder children. Journal of Abnormal Child Psychology, 19, 35–52.CrossRefGoogle Scholar
  3. Barkley, R. A., (2006). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed.). New York: Guilford Press.Google Scholar
  4. Barkley, R. A., Anderson, D. L., & Kruesi, M. (2007). A pilot study of the effects of Atomexetine on driving in adults with ADHD. Journal of Attention Disorders, 10, 306–316.CrossRefGoogle Scholar
  5. Barkley, R. A., & Cunningham, C. E. (1979). Stimulant drugs and activity level in hyperactive children. American Journal of Orthopsychiatry, 49,491–499.CrossRefGoogle Scholar
  6. Barkley, R. A., & Cunningham, C. E. (1980). The parent-child interactions of hyperactive children and their modification by stimulant drugs. In R. Knights & D. Bakker (Eds.), Treatment of hyperactive and learning disabled children (pp. 219–236). Baltimore, MD: University Park Press.Google Scholar
  7. Barkley, R. A., DuPaul, G. J., & McMurray, M. B. (1991). Attention deficit disorder with and without hyperactivity: Clinical response to three doses of methylphenidate. Pediatrics, 87, 519–531.PubMedGoogle Scholar
  8. Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2006). Young adult outcome of hyperactive children: Adaptive functioning in major life activities. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 192–202.CrossRefGoogle Scholar
  9. Barkley, R. A., Murphy, K. R., & Fischer, M. (2008). ADHD in adults: What the science says. New York: Guilford Press.Google Scholar
  10. Bhatia, S. K., Rezac, A. J., Vitiello, B., Sitorius, M. A., Buehler, B. A. & Kratochvil, C. J. (2008). Antidepressant prescribing practices for the treatment of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 18(1), 70–80.CrossRefGoogle Scholar
  11. Biederman, J., Faraone, S., Monuteaux, M., & Grossbard, J. (2004). How informative are parent reports of ADHD symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents’ and teachers’ reports. Pediatrics, 113(6), 1667–1671.CrossRefGoogle Scholar
  12. Birmaher, B. (1998). Should we use antidepressant medications for children and adolescents with depression? Psychopharmacology Bulletin, 34, 245–251.Google Scholar
  13. Birmaher, B., & Brent, D. A. (2003). Antidepressants: II: Tricylic agents. In A. Martin, L. Scahill, D. S. Chaney, & J. F. Leckman (Eds.), Pediatric psychopharmacology: Principles and practice (pp. 466–483). New York: Oxford University Press.Google Scholar
  14. Bohnstedt, B. N., Kronenberger, W. G., Dunn, D. W., Giaugue, A. L., Wood, E. A., Rembusch, M. E., et al. (2005). Investigator ratings of ADHD symptoms during a randomized trial of Atomoxetine: A comparison of parents and teachers as informants. Journal of Attention Disorders, 8(4), 153–159.CrossRefGoogle Scholar
  15. Bostic, J. Q., Prince, J., Frazier, J., DeJong, S., & Wilens, T. E. (2003). Pediatric psychopharmacology update. Psychiatric Times, 20, 9.Google Scholar
  16. Brent, D., Emslie, G., Clarke, G., Wagner, K., Asarnow, J., Keller, M., et al. (2008). Switching to another SSRI or to Venlafaxine with and without cognitive behavioral therapy for adolescents with SSRI-resistant depression. JAMA, 299(8), 901–913.CrossRefGoogle Scholar
  17. Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA, 297(15), 1683–1696.CrossRefGoogle Scholar
  18. Carlson, C. L., Pelham, W. E., Milich, R., & Dixon, M. (1992). Single and combined effects of methylphenidate and behavior therapy on the classroom behavior, academic performance, and self-evaluations of children with attention deficit hyperactivity disorder. Journal of Abnormal Child Psychology, 202, 213–232.CrossRefGoogle Scholar
  19. Comings, D. E. (1990). Tourette syndrome and human behavior. Durante, CA; Hope Press.Google Scholar
  20. Connor, D. F. (2006). Stimulants. In R.A. Barkley, Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (3rd ed., pp. 608–647). New York: Guilford Press.Google Scholar
  21. Corkum, P., Panton, R., Ironside, S., MacPherson, M., & Williams, T. (2008). Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder. Journal of Pediatric Psychology, 33(4), 368–379.CrossRefGoogle Scholar
  22. Doehring, D. G. (1968). Patterns of impairment in specific reading disability: A neuropsychological investigation. Bloomington: Indiana University Press.Google Scholar
  23. Dubovsky, S. L. (1992). Psychopharmacological treatment in neuropsychiatry. In S. C. Yudofsky & R. E. Hales (Eds.), The American Psychiatric Press textbook of neuropsychiatry (2nd ed., pp. 663–702). Washington, DC: American Psychiatric Press.Google Scholar
  24. DuPaul, G., & Stoner, Ga. (2003). ADHD in the schools: Assessment and intervention strategies (2nd ed.). New York: Guilford Press.Google Scholar
  25. DuPaul, G., Barkley, R. A., & McMurphy, M. B. (1991). Therapeutic effects of medication on ADHD: Implications for school psychologists. School Psychology Review, 20,203–219.Google Scholar
  26. DuPaul, G. J., McGoey, K. E., & Mautone, J. A. (2003). Pediatric pharmacology and psychopharmacology. In M. C. Roberts (Ed.), Handbook of pediatric psychology (3rd ed. pp. 234–252). New York: Guilford Press.Google Scholar
  27. Faraone, S. V., Wigal, S. B., & Hodgins, P. (2007). Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and Atomoxetine (Stratttera) in school-aged children with ADHD. Journal of Attention Disorders, 11(1), 74–82.CrossRefGoogle Scholar
  28. Gadow, K. D., & Poling, A. G. (1988). Pharmacotherapy and mental retardation. Boston: College Hill Press.Google Scholar
  29. Ghuman, J. K., Riddle, M. A., Vitiello, B., Greenhill, L. L., Ghuang, S., Wigal, S. et al. (2007). Comorbidity moderates response to methylphenidate in the preschoolers with attention deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17(5), 563–580.CrossRefGoogle Scholar
  30. Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J.J. (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163, 1898–1904.CrossRefGoogle Scholar
  31. Green, W. H. (1991). Child and adolescent clinical psychopharmacology. Baltimore, MD: Williams & Wilkins.Google Scholar
  32. Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J., et al. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 45(11), 1284–1293.CrossRefGoogle Scholar
  33. Handen, B. L., & Gilchrist, R. (2006). Practitioner review: Psychopharmacology in children with mental retardation. Journal of Child Psychology and Psychiatry, 47(9), 871–882.CrossRefGoogle Scholar
  34. Hasler, G., Fromm, S., Carlson, P. J., Luckenbaugh, D. A., Waldeck ,T., Geraci, M.,et al. (2008). Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Archives of General Psychiatry, 65(5), 521–531.CrossRefGoogle Scholar
  35. Hinshaw, S. P. (1991). Stimulant medication and the treatment of aggression in children with attention deficits. Journal of Clinical Child Psychology, 20, 301–312.CrossRefGoogle Scholar
  36. Hinshaw, S. P., Henker, B., Whalen, C. K., Erhardt, D., & Dunnington, R. E. (1989). Aggressive, prosocial, and nonsocial behavior in hyperactive boys: Dose effects of methylphenidate in naturalistic settings. Journal of Consulting and Clinical Psychology, 57, 636–443.CrossRefGoogle Scholar
  37. Hunt, R. D., Mandl, L., Lau, S., & Hughes, M. (1991). Neurobiological theories of ADHD and Ritalin. In L. Greenhill (Ed.), Ritalin theory and practice (pp. 267–287). New York: Mary Ann Leibert PressGoogle Scholar
  38. Jacobvitz, D., Sroufe, L. A., Stewart, M., & Leffert, N. (1990). Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: A comprehensive review. Journal of the American Academy of Child & Adolescent Psychiatry. 29(5), 677–688.CrossRefGoogle Scholar
  39. Joshi, P. T., Cappozzoli, J. A., & Coyle, J. T. (1988). Low-dose neuroleptic therapy for children with child-onset pervasive developmental disorder. American Journal of Psychiatry, 145,335–338.CrossRefGoogle Scholar
  40. Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., et al. (2004). Once-daily Atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo controlled trial. Pediatrics, 114 (1), e1–e8.CrossRefGoogle Scholar
  41. Kratochvil, C., Heiligenstein, J., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child & Adolescent Psychiatry. 41(7), 776–784.CrossRefGoogle Scholar
  42. McGough, J. J., Wigal, S., Abikoff, H., Turnbow, J. M., Posner, K., & Moon, E. (2006). A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. Journal of Attention Disorders, 9(3), 476–485.CrossRefGoogle Scholar
  43. MTA Cooperative Group. (2004a). National Institute of Mental Health Multimodal Treatment Study of Attention-deficit/hyperactivity disorder. Pediatrics, 113, 754–761.CrossRefGoogle Scholar
  44. MTA Cooperative Group. (2004b). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics, 113, 762–769.CrossRefGoogle Scholar
  45. MTA Cooperative Group. (2008a). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with AD/HD (MTA): Part I: Executive summary. Journal of Attention Disorders, 12(1), 3–13.CrossRefGoogle Scholar
  46. MTA Cooperative Group. (2008b). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with AD/HD (MTA): Part II: Supporting details. Journal of Attention Disorders, 12(1), 14–41.Google Scholar
  47. MTA Research Symposium (2007, November). Key impact of the MTA study: What is the take-home message. Paper presented at the 20th Anniversary Hall of Fame Conference, CHADD. Crystal City, VA.Google Scholar
  48. Neppe, V. M., & Tucker, G. J. (1992). Neuropsychiatric aspects of seizure disorders. In S. C. Yudofsky & R. E. Hales (Eds.), The American Psychiatric Press textbook of neuropsychiatry (2nd ed., pp. 397–425). Washington, DC: American Psychiatric Press.Google Scholar
  49. NIMH. (2007). Medications with Adendum January 2007. Department of Health and Human Services. National Institute of Health.Google Scholar
  50. Olfson M., Marcus S. C., & Shaffer D. (2006). Antidepressant drug therapy and suicide in severely depressed children and adults. Archives of General Psychiatry, 63, 865–872.CrossRefGoogle Scholar
  51. Pelham, W. E. (1993). Pharmacotherapy for children with attention deficit-hyperactivity disorder. School Psychology Review, 22, 1–227.Google Scholar
  52. Pelham, W. E., Schnedler, R, W., Bender, M. E., Nilsson, D. E., Miller, J., Budrow, M. S., et al. (1988). The combination of behavior therapy and methylphenidate in the treatment of attention deficit disorders. In L. Bloomingdale (Eds.), Attention deficit disorder (Vol. 3, pp. 29–48). New York: Pergamon Press.Google Scholar
  53. Pellock, J. M. (1987). Carbamazepine side effects in children and adults. Epilepsia, 28, S64–S70.CrossRefGoogle Scholar
  54. Phelps, L., Brown, R. T., & Power, T. J. (2002). Pediatric psychopharmacology: Combining medical and psychosocial interventions.NY: Guilford Press.CrossRefGoogle Scholar
  55. Pliszka, S. R. (2003). Neuroscience of mental health clinicians. New York: Guilford Press.Google Scholar
  56. Pliszka, S. R., Carlson, C. L., & Swanson, J. M. (1999). ADHD with comorbid disorders. New York: Guilford Press.Google Scholar
  57. Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., et al. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Controlled Clinical Trials, 25(1), 119–142.CrossRefGoogle Scholar
  58. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A., Stewart, J. W., Warden, D., et al. (2006). Acute and longer-term outcomes in depressed outpatients who required one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.CrossRefGoogle Scholar
  59. Salzman, C. (1990). Benzodiazepine dependency: Summary of the APA task force on benzodiapines. Psychopharmacology Bulletin, 26, 61–62.Google Scholar
  60. Safer, D. (2006). Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders? Pediatrics, 118(3), 1248–1251.CrossRefGoogle Scholar
  61. Schaughency, E. A., & Hynd, G. W. (1989). Attentional control systems and the attentional deficit disorders (ADD). Learning and Individual Differences, 4, 42–449.Google Scholar
  62. Scheffer, R. E., Kowatch, R. A., Carmody, T., & Rush, A. J. (2005). Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. American Journal of Psychiatry, 162(1):58–64.CrossRefGoogle Scholar
  63. Silva, R. R., Munoz, D. M., & Alpert, M. (1996). Carbamazepine use in children: Adolescents with features of attention-deficit hyperactivity disorders: A meta-analysis. The American Academy of Child and Adolescent Psychiatry, 35(3), 352–358.CrossRefGoogle Scholar
  64. Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. (2006). Suicide risk during antidepressant treatment. American Journal of Psychiatry, 163(1), 41–47.CrossRefGoogle Scholar
  65. Swanson, J., Greenhill, L. L., Wigal, T., Kollins, S., Stehli, A. M., Davies, M., et al. (2006). Stimulant-related reductions of growth rates in the PATS. Journal of Child and Adolescent Psychopharmacology, 45(11), 1304–1313.CrossRefGoogle Scholar
  66. Treatment for Adolescents with Depression Study (TADS) Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 292(7):807–820.CrossRefGoogle Scholar
  67. Taylor, E. Anderson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Dopfner, M., et al. (2004). Clinical guidelines for hyperkinetic disorder. European Child and Adolescent Psychiatry, 13(Suppl. 1), 17–130.Google Scholar
  68. US Food & Drug Administration. (2004). Background on suicidality associated with antidepressant drug treatment. Retrieved from
  69. Vetter, V. L., Elia, J., Erickson, C., Berger, S., Nathan Blum, N., Uzark, K., et al. (2008). Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation; 117, 2407–2423.Google Scholar
  70. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., et al. (2002). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications. Synapse, 43, 181–187.CrossRefGoogle Scholar
  71. Weissman, M. M., Pilowsky, D. J., Wickramaratne, P. J., Talati, A., Wisniewski, S. R., Fava, M., et al. (2006). Remission in maternal depression and child psychopathology: A STAR*D-Child report. JAMA, 295, 1389–1398.CrossRefGoogle Scholar
  72. Weizman, A., Weitz, R., Szekely, G. A., Tyana, S., & Belmaker, R. H. (1984). Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. Journal of American Academy of Child Psychiatry, 23,295–298.CrossRefGoogle Scholar
  73. Wilens, T. E. (2001). Straight talk about psychiatric medications for kids. New York: Guilford Press.Google Scholar
  74. Wilens, T. E., & Spencer, T. J. (1999). Debate: Combining methylphenidate and clonidine: A clinically sound medication option. Journal of the Child and Adolescent Psychiatry, 38, 614–622.CrossRefGoogle Scholar
  75. Wilens, T. E., & Spencer, T. J. (2000). The stimulants revisited. Child and Adolescent Psychiatric Clinics of North America, 9(3), 573–603.PubMedGoogle Scholar
  76. Wood, J. G., Crager, J. L., Delap, C. M., & Heiskell, K. D. (2007). Beyond methylphenidate: Nonstimulant medications for youths with ADHD. Journal of Attention Disorders, 11(3), 341–350.CrossRefGoogle Scholar
  77. Zametkin, A. J., & Liotta W. (1998). The neurobiology of attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 59(Suppl 7), 17–23.PubMedGoogle Scholar
  78. Zametkin, A. J., & Rapoport, J. L. (1986). The pathophysiology of attention deficit disorder with hyperactivity. In B. B. Lahey & A. E. Kazdin (Eds.), Advances in clinical child psychology (Vol. 9, pp. 177–216). New York: Plenum Press.CrossRefGoogle Scholar
  79. Zametkin, A., & Rapoport, J. L. (1987). Noradrenergic hypothesis of attention deficit disorder with hyperactivity: A critical review. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 837–842). New York: Raven Press.Google Scholar
  80. Zametkin, A., Rapoport, J. L., Murphy, D. L., Linnoila, M., & Ismond, D. (1985). Treatment of hyperactive children with monamine oxidase inhibitors: I. Clinical efficacy. Archives of General Psychiatry, 42, 962–966.CrossRefGoogle Scholar
  81. Zisook, S., Lesser, I., Stewart, J. W., Wisniewski, S. R., Balasubramani, G. K., Fava, M., et al. (2007). Effect of age at onset on the course of major depressive disorder. American Journal of Psychiatry 164, 1539–1546.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Margaret Semrud-Clikeman
    • 1
  • Phyllis Anne Teeter Ellison
    • 2
  1. 1.Michigan State UniversityLansingUSA
  2. 2.Department of Educational PsychologyUniversity of WisconsinMilwaukeeUSA

Personalised recommendations